IDXX - IDEXX Laboratories, Inc.
Assenagon Asset Management S.A. raised its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 39.9% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 256,362 shares of the company's stock after buying an additional 73,129 shares during the quarter. Assenagon Asset Management S.A. owned about 0.33%
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (Nasdaq: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 third quarter financial results for Monday, November 2, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q3 2026 Earnings Snapshot through a link on the IDEXX websi.
Transaction marks the first realization from the now closed specialist animal health fund's inaugural vehicle CHICAGO, Sept. 30, 2026 /PRNewswire/ -- Chicago Pacific Founders ("CPF") today announced the exit of its investment in CoVetAI Inc. ("CoVet") following the company's acquisition by IDEXX Laboratories, Inc. (NASDAQ: IDXX).
IDEXX's CAG growth, expanding software adoption and global gains face headwinds from FX and weaker U.S. vet visits.
IDEXX Laboratories (NASDAQ: IDXX) executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits. Chief Executive Officer Mike Erickson said the company had an "exceptional" second quarter and a strong start to
IDEXX Laboratories (NASDAQ: IDXX) executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers. Chief Executive Officer Mike Erickson said IDEXX had an "exceptional Q2" and a strong start to the year, prompting the company to raise
IDEXX Laboratories NASDAQ: IDXX executives highlighted the company's diagnostic innovation pipeline, recurring-revenue growth and commercial investments during the Morgan Stanley Global Healthcare Conference, while reaffirming confidence in its long-term growth framework despite continued pressure on veterinary office visits.
IDEXX Laboratories NASDAQ: IDXX executives reiterated the company's long-term growth framework at the Morgan Stanley Global Healthcare Conference, citing demand for veterinary diagnostics, product innovation, commercial investments and recurring-revenue economics as key drivers.
IDXX shares rise 0.6% after the company acquires CoVet, expanding its AI-native software capabilities to improve veterinary workflows, diagnostics and practice performance.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the expansion of its Faecal Dxâ¢antigen testing platform
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX expands Faecal Dx™ antigen testing platform in the United Kingdom with taeniid tapeworm detection for broader intestinal parasite screening.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX announces acquisition of CoVetAI to advance veterinary workflow intelligence.
IDEXX Laboratories, Inc. (IDXX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
InMode (NASDAQ: INMD - Get Free Report) and IDEXX Laboratories (NASDAQ: IDXX - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings. Risk and Volatility InMode has a beta of 1.86,
The transaction involved 2,203 shares at $532.08 per share for a total value of ~$1.2 million. The director traded shares equal to 23% of the stake held before the filing.
Baird Financial Group Inc. decreased its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 7.9% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 76,035 shares of the company's stock after selling 6,500 shares during the period. Baird Financial Group Inc. owned 0.10% of
Arizona State Retirement System raised its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 4.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,772 shares of the company's stock after acquiring an additional 1,074 shares during the quarter.
California State Teachers Retirement System raised its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 50,115.1% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,590,848 shares of the company's stock after purchasing an additional 61,468,194 shares
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock?
Baron Focused Growth Fund rebounded in Q2 from a disappointing start to the year, with the Fund gaining 13.26% compared with a gain of 24.02% for the Russell 2500 Growth Index. We remain steadfast in our commitment to long-term investing in competitively advantaged, growth businesses. As of June 30, 2026, the Fund owned 28 investments.